Researcher.Life Logo

Experimental Hematology and Oncology : Impact Factor & More

eISSN: 2162-3619pISSN: 2162-3619
JournalOpen Access

Key Metrics

CiteScore
8.1
Eigenfactor
0.001 - 0.005
Impact Factor
5 - 10
SJR
Q2Oncology
SNIP
1.39
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Experimental Hematology and Oncology

Experimental Hematology and Oncology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2590 | USD 2990 | GBP 2290
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in Experimental Hematology and Oncology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Experimental Hematology and Oncology

MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc.
  • 24 Jun 2026
  • Experimental hematology & oncology
Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.
  • 21 Jun 2026
  • Experimental hematology & oncology
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.
  • 20 Jun 2026
  • Experimental hematology & oncology
A multimodal single-cell framework for ecosystem-level profiling of circulating tumor and non-tumor cells.
  • 19 Jun 2026
  • Experimental hematology & oncology
Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.
  • 19 Jun 2026
  • Experimental hematology & oncology
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
  • 19 Jun 2026
  • Experimental hematology & oncology
MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc.
  • 24 Jun 2026
  • Experimental hematology & oncology
Biology-informed risk stratification of glioblastoma by integrating MRI-based intratumoral heterogeneity with clinical features: a multicenter validation study.
  • 21 Jun 2026
  • Experimental hematology & oncology
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.
  • 20 Jun 2026
  • Experimental hematology & oncology
A multimodal single-cell framework for ecosystem-level profiling of circulating tumor and non-tumor cells.
  • 19 Jun 2026
  • Experimental hematology & oncology
Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.
  • 19 Jun 2026
  • Experimental hematology & oncology
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
  • 19 Jun 2026
  • Experimental hematology & oncology

FAQs on Experimental Hematology and Oncology